Results 251 to 260 of about 45,588 (281)
Some of the next articles are maybe not open access.
Phosphodiesterase type 5 inhibitors and endothelial function
Current Sexual Health Reports, 2007Erectile dysfunction (ED) and endothelial dysfunction are common in individuals with multiple cardiovascular risk factors (CRFs) and are longitudinal predictors of cardiovascular events. ED is associated with systemic endothelial cell activation/dysfunction independent from CRFs or from diffuse, unrecognized vascular damage.
Antonio Aversa, Roberto Bruzziches
openaire +1 more source
Vision Disorders and Phosphodiesterase Type 5 Inhibitors
Drug Safety, 2009Phosphodiesterase type 5 (PDE-5) inhibitors (sildenafil, vardenafil and tadalafil) have been in widespread use for the safe and effective treatment of erectile dysfunction (ED) for nearly a decade. During that time, a relatively small number of patients have experienced adverse visual events, including nonarteritic anterior ischaemic optic neuropathy ...
openaire +2 more sources
Chronic dosing of phosphodiesterase type 5 inhibitors
Current Sexual Health Reports, 2008Ten years ago, the introduction of sildenafil citrate for the treatment of erectile dysfunction fundamentally changed the field of sexual medicine. The sexual indications, along with the pharmacologic characteristics of this drug, led to its approval for on-demand use.
openaire +1 more source
Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors
Vascular, 2013Thromboangiitis obliterans, or Buerger’s disease, is a non-atherosclerotic, segmental, inflammatory disease affecting the small- and medium-sized vessels of the distal extremities. Other than discontinuation of tobacco, there is no standard-of-care treatment. Although two randomized trials have demonstrated a role for intravenous iloprost, no oral drug
Aryeh M, Abeles +3 more
openaire +2 more sources
Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction
World Journal of Urology, 2005Erectile dysfunction (ED) affects the sexual lives of millions of men. The first-line oral pharmacotherapy for most ED patients is phosphodiesterase type-5 (PDE-5) inhibitors, of which three are available. Sildenafil is the most widely prescribed oral agent for ED and has a very satisfactory efficacy-safety profile in all patient categories.
BRIGANTI , ALBERTO +6 more
openaire +3 more sources
Optimizing response to phosphodiesterase type 5 inhibitors
Current Sexual Health Reports, 2007Although using phosphodiesterase type 5 inhibitors to treat erectile dysfunction has been highly effective in clinical trials, many men do not achieve their desired goals and stop using the medication after a few attempts. The notion of optimizing response to pharmacologic interventions is relatively new to clinicians.
openaire +1 more source
[Erectile dysfunction and phosphodiesterase type 5 inhibitors].
Revue medicale de Bruxelles, 2003Erectile dysfunction affects 150 millions of men and its prevalence increases with age. The improvement of life expectancy will increase the worldwide prevalence to 300 million in 2025. Oral treatments are nowadays the first line therapy for the vast majority of people as they have a good reliability and tolerance and restore more spontaneity.
T, Roumeguère +2 more
openaire +1 more source
[Novel indications for phosphodiesterase type 5 inhibitors].
Medizinische Klinik (Munich, Germany : 1983), 2007Phosphodiesterase type 5 (PDE5) induces the breakdown of cyclic guanosine monophosphate (cGMP) in smooth muscle cells. Hence, PDE5 inhibitors promote vasodilative effects by enhancing intracellular cGMP levels. Three PDE5 inhibitors, sildenafil, vardenafil, and tadalafil, have been approved for the treatment of "erectile dysfunction" (ED).
Stephan, Rosenkranz +2 more
openaire +1 more source
The use of phosphodiesterase type 5 inhibitors for erectile dysfunction
Current Opinion in Urology, 2004MONTORSI, FRANCESCO +4 more
openaire +3 more sources